Alvimopan Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 12 mg
Reference Brands: Entereg (USA)
Category: Gastrointestinal Drugs
Alvimopan is available in Capsules and strengths such as 12 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Alvimopan is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Alvimopan can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Alvimopan, marketed under the trade name Entereg, is a peripherally acting μ-opioid receptor antagonist used to treat postoperative ileus. Unlike centrally acting opioid antagonists, alvimopan has limited ability to cross the blood–brain barrier, allowing it to block μ-opioid receptors in the gastrointestinal tract without reversing the analgesic effects of opioids in the central nervous system. This selective action helps patients recover bowel function more quickly after surgery while still managing pain effectively with opioid medications.
Alvimopan is primarily prescribed for hospitalized patients following bowel resection surgery. It is administered orally in a controlled hospital setting, typically starting prior to surgery and continuing for a limited number of doses postoperatively. By stimulating gastrointestinal motility and reducing the duration of postoperative ileus, alvimopan can shorten hospital stays and improve patient comfort and recovery outcomes. Its use is restricted to FDA-approved indications due to potential cardiovascular risks with long-term administration. When used appropriately under medical supervision, alvimopan is an effective agent for managing postoperative gastrointestinal complications without compromising pain control.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Alvimopan is used to accelerate gastrointestinal recovery following bowel resection surgery. It helps reduce postoperative ileus while allowing continued use of opioid pain medications.
Alvimopan is a synthetic peripherally acting μ-opioid receptor antagonist formulated as an oral capsule for short-term hospital use.
Alvimopan is marketed under the brand name Entereg in the USA.
Alvimopan (Entereg) is manufactured and marketed by Merck & Co. in the United States.
The generic name is alvimopan.
The brand name is Entereg (USA).
Alvimopan is manufactured in FDA-approved pharmaceutical facilities in the USA under Merck & Co. supervision.
Related Products
Naloxegol Oxalate
Strength:
12.5 mg, 25 mg
Form: Tablets
Reference Brands: Movantik (USA), Moventig (EU)
View Details
Methscopolamine Bromide
Strength:
2.5 mg, 5 mg
Form: Tablets
Reference Brands: Pamine (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
